Pfizer Inc. 2004 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for Pfizer Inc. for the fiscal year ended December 31, 2004. Pfizer is a research-based, global pharmaceutical company operating in three primary segments: Human Health, Consumer Healthcare, and Animal Health. The company completed the acquisition of Esperion Therapeutics, Inc. in February 2004 for $1.3 billion in cash. As of December 31, 2004, the company employed approximately 115,000 people worldwide.
Key Financial Metrics
While specific consolidated totals for revenue, net income, and cash flow are incorporated by reference from the 2004 Financial Report and not explicitly stated in the provided text, the following segment data and metrics are disclosed:
- Human Health Segment: Revenues increased 17% to $46.1 billion, contributing 88% of total revenues.
- Consumer Healthcare Segment: Revenues increased 19% to $3.5 billion, contributing 7% of total revenues.
- Animal Health Segment: Revenues increased 22% to $2.0 billion, contributing 3.7% of total revenues.
- Research and Development (R&D): Total spending was $7.7 billion in 2004 (compared to $7.5 billion in 2003).
- Geographic Mix: U.S. operations accounted for 56% of revenues; international operations accounted for 44% ($23 billion).
- Top Customers: Sales to the three largest customers (McKesson, Cardinal Health, AmerisourceBergen) represented 18.2%, 13.8%, and 12.6% of total revenues, respectively.
- Stock Repurchases: In Q4 2004, the company purchased approximately 69.2 million shares under its 2003 and 2004 programs, with approximately $3.3 billion remaining available under the 2004 program as of year-end.
Note: The filing text does not provide a clear value for consolidated net income, operating margins, total debt, or free cash flow.
Material Changes vs. Prior Period
- Revenue Growth: All three major business segments experienced double-digit revenue growth in 2004 compared to 2003.
- Acquisition Impact: The inclusion of a full year of Pharmacia product sales contributed to revenue increases across segments.
- Foreign Exchange: Favorable foreign exchange movements positively impacted reported revenues in many countries.
- Patent Expirations and Generic Competition: Several key products faced patent expirations or generic competition in 2004, including Norvasc (Europe), Accupril (U.S.), Neurontin (U.S.), and Diflucan (U.S.). The company responded by launching its own generic versions of Accupril, Neurontin, and Diflucan through its Greenstone Ltd. subsidiary.
- Product Launches: New approvals and launches included Caduet (U.S.), Inspra (U.S. and E.U.), Spiriva HandiHaler (U.S.), and Macugen (U.S.).
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: Management emphasizes innovation and R&D investment as critical to future success, with approximately 225 projects in development. The company plans to convert prescription medications to over-the-counter (OTC) products where market conditions permit (e.g., Zantac 150 launched in Jan 2005).
Key Risks and Contingencies:
- Patent Expirations: Significant risk of revenue loss upon expiration of patents for major products like Lipitor (2010), Zoloft (2006), and Zithromax (2005). Generic competition is a major challenge.
- Regulatory and Pricing Pressure: Intense pressure from Managed Care Organizations (MCOs), government price controls (especially in Europe), and the implementation of the 2003 Medicare Act.
- Product Safety and Litigation: Ongoing FDA and EMEA reviews of COX-2 inhibitors (Celebrex and Bextra) pose a risk of significant sales loss. The company faces various patent, product liability, and environmental litigations.
- Foreign Exchange: 44% of revenues are international, exposing the company to currency fluctuation risks.
- Environmental Compliance: Incurred $68 million in capital expenditures and $274 million in other expenses for environmental compliance in 2004.
Investor Verification Checklist
- Verify the specific consolidated revenue, net income, and cash flow figures in the 2004 Financial Report (incorporated by reference), as they are not explicitly listed in the 10-K text provided.
- Monitor the status of FDA/EMEA reviews for Celebrex and Bextra and the potential impact on sales.
- Track the timeline and impact of patent expirations for Lipitor, Zoloft, and Zithromax.
- Review the Legal Proceedings and Contingencies section (Note 17) for details on pending litigation and environmental liabilities.
- Assess the impact of the 2003 Medicare Act on future pricing and volume.
- Confirm the integration progress and synergy realization from the Pharmacia acquisition.